ArticleInternational journal of obesity (2005)2026
Association between metabolic signatures of predicted VAT mass and risk of MASLD and other chronic liver diseases.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsVisceral adipose tissue (VAT) plays a key role in metabolic dysfunction, and it is increasingly recognised as a contributor to metabolic dysfunction-associated steatotic liver disease (MASLD) and other chronic liver conditions. However, the systemic metabolic pathways linking VAT to liver disease remain unclear. This study aimed to identify metabolic signatures associated with VAT and examine their potential role as mediators in the relationship between VAT accumulation and the risks of MASLD, cirrhosis and hepatoma.
methodsThis prospective study included 269,018 UK Biobank participants without baseline liver disease. Predicted VAT mass was estimated using sex-specific models on the basis of anthropometric and bioimpedance measures. Incident liver outcomes were identified via ICD-coded hospital records. A VAT-related metabolic signature was derived from 251 circulating metabolites by using elastic net regression. Associations with liver disease risks were assessed using Cox models. Mediation analysis estimated the proportion of the VAT-MASLD association explained by the metabolic signature.
resultsOver a median follow-up of 14.3 years, 2658 MASLD, 671 cirrhosis and 444 hepatoma cases occurred. Each standard deviation increase in VAT was associated with increased risks of MASLD (HR: 1.70; 95% CI: 1.62-1.79), cirrhosis (HR: 1.27; 95% CI: 1.15-1.40) and hepatoma (HR: 1.15; 95% CI: 1.02-1.30). The VAT-related metabolic signature (156 metabolites, primarily lipoprotein subclasses and lipids) was independently associated with MASLD (HR: 1.89; 95% CI: 1.72-2.08) and mediated 40.0% of the VAT-MASLD association. No significant mediation was observed for cirrhosis or hepatoma.
conclusionsVAT and its metabolic signature are strongly associated with MASLD risk, partly explaining its pathogenesis through systemic metabolic alterations.
Indexed as
Identifiers
41922508What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.